High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment

[1]  S. Shariat,et al.  Accurate preoperative prediction of non‐organ‐confined bladder urothelial carcinoma at cystectomy , 2013, BJU international.

[2]  J. McKiernan,et al.  Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? , 2012, BJU international.

[3]  M. Cosentino,et al.  [A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors]. , 2012, Actas urologicas espanolas.

[4]  C. Bayer,et al.  Nuclear matrix protein‐22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study , 2012, BJU international.

[5]  Jinsung Park,et al.  Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor. , 2012, Journal of endourology.

[6]  Kerstin Amann,et al.  The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer , 2012, BJU international.

[7]  R. Sylvester,et al.  Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. , 2012, European urology.

[8]  Andrea Minervini,et al.  A comparison of hexaminolevulinate (Hexvix®) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study , 2012, Surgical Endoscopy.

[9]  T. Ørntoft,et al.  Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. , 2012, The American journal of pathology.

[10]  Sunjay Jain,et al.  GOOD QUALITY WHITE‐LIGHT TRANSURETHRAL RESECTION OF BLADDER TUMOURS (GQ‐WLTURBT) WITH EXPERIENCED SURGEONS PERFORMING COMPLETE RESECTIONS AND OBTAINING DETRUSOR MUSCLE REDUCES EARLY RECURRENCE IN NEW NON‐MUSCLE‐INVASIVE BLADDER CANCER: VALIDATION ACROSS TIME AND PLACE AND RECOMMENDATION FOR BENCHMAR , 2012, BJU international.

[11]  C. Pan,et al.  Prognostic Significance in Substaging of T1 Urinary Bladder Urothelial Carcinoma on Transurethral Resection , 2012, The American journal of surgical pathology.

[12]  B. Geavlete,et al.  Treatment changes and long‐term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non‐muscle‐invasive bladder cancer (NMIBC)? , 2012, BJU international.

[13]  T. H. van der Kwast,et al.  A new and highly prognostic system to discern T1 bladder cancer substage. , 2012, European urology.

[14]  J. Chin,et al.  Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? , 2012, World Journal of Urology.

[15]  A. Vlahou,et al.  Profilin 1 is a Potential Biomarker for Bladder Cancer Aggressiveness* , 2011, Molecular & Cellular Proteomics.

[16]  Raj Persad,et al.  A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. , 2011, The Journal of urology.

[17]  L. Martínez-Piñeiro,et al.  The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. , 2011, European urology.

[18]  J. Witjes,et al.  Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. , 2011, European urology.

[19]  R. Meijer,et al.  The risk profiles of three clinical types of carcinoma in situ of the bladder , 2011, BJU international.

[20]  J. P. Burgués,et al.  Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group , 2011 .

[21]  H. Grossman,et al.  Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. , 2011, European urology.

[22]  J. Burgués,et al.  Diagnóstico fotodinámico con hexaminolevulinato en el cáncer vesical no músculo invasivo: experiencia del grupo BLUE , 2011 .

[23]  Carsten Wiuf,et al.  Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.

[24]  J. Serth,et al.  Decreased Galectin-8 Is a Strong Marker for Recurrence in Urothelial Carcinoma of the Bladder , 2011, Urologia Internationalis.

[25]  F. Algaba,et al.  Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. , 2011, European urology.

[26]  A. Gross,et al.  Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience , 2011, World Journal of Urology.

[27]  U. Nagele,et al.  Waterjet hydrodissection: first experiences and short-term outcomes of a novel approach to bladder tumor resection , 2011, World Journal of Urology.

[28]  A. Hartmann,et al.  The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer , 2011, BJU international.

[29]  A. Hartmann,et al.  Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. , 2010, American journal of clinical pathology.

[30]  Y. Lotan,et al.  Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. , 2010, Urologic oncology.

[31]  C. Stief,et al.  CEACAM1: a novel urinary marker for bladder cancer detection. , 2010, European urology.

[32]  Dieter Jocham,et al.  Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. , 2010, European urology.

[33]  G. Steineck,et al.  Diagnostic random bladder biopsies: Reflections from a population-based cohort of 538 patients , 2010, Scandinavian journal of urology and nephrology.

[34]  A. Bohle.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer , 2009 .

[35]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[36]  F. Algaba,et al.  Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. , 2009, European urology.

[37]  V. Lokeshwar,et al.  Potential new urinary markers in the early detection of bladder cancer , 2009, Current opinion in urology.

[38]  Y. Lotan,et al.  Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. , 2009, The Journal of urology.

[39]  Liang Cheng,et al.  Staging and reporting of urothelial carcinoma of the urinary bladder , 2009, Modern Pathology.

[40]  T. Hajdinjak.  UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. , 2008, Urologic oncology.

[41]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[42]  J. Witjes,et al.  Urinary markers in bladder cancer. , 2008, European urology.

[43]  L. Martínez-Piñeiro,et al.  Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. , 2008, European urology.

[44]  M. Babjuk,et al.  Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. , 2008, Urology.

[45]  J. Jones,et al.  Defining the role of NMP22 in bladder cancer surveillance , 2008, World Journal of Urology.

[46]  M. Raitanen,et al.  The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies , 2008, World Journal of Urology.

[47]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[48]  T. Ebert,et al.  Immunocytology in the assessment of patients with asymptomatic microhaematuria. , 2007, European urology.

[49]  A. Vickers,et al.  Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. , 2007, The Journal of urology.

[50]  Y. Lotan,et al.  Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. , 2006, Urology.

[51]  A. Rosales,et al.  Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. , 2006, Journal of Urology.

[52]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[53]  H. Woo,et al.  Management of stage T1 tumors of the bladder: International Consensus Panel. , 2005, Urology.

[54]  H. Herr.  Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. , 2005, The Journal of urology.

[55]  J. Witjes,et al.  High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. , 2005, Urology.

[56]  Dieter Jocham,et al.  Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. , 2005, The Journal of urology.

[57]  A. Pycha,et al.  The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. , 2005, Anticancer research.

[58]  A. Orsola,et al.  Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. , 2005, European urology.

[59]  F. Wiklund,et al.  Results of second-look resection after primary resection of T1 tumour of the urinary bladder , 2005, Scandinavian journal of urology and nephrology.

[60]  J. Montie.  Prognosis of Muscle-Invasive Bladder Cancer: Difference Between Primary and Progressive Tumours and Implications for Therapy , 2005 .

[61]  M. Soloway.  Re: Schrier BPh, Hollander MP, van Rhijn BWG, Kiemeney LALM, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004;45:292-6. , 2005, European urology.

[62]  B. Malavaud.  T1G3 bladder tumours: the case for radical cystectomy. , 2004, European urology.

[63]  M. Soloway,et al.  Expectant management of small, recurrent, noninvasive papillary bladder tumors. , 2003, The Journal of urology.

[64]  Dieter Jocham,et al.  Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. , 2003, The Journal of urology.

[65]  L. Martínez-Piñeiro,et al.  Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille calmette-guérin with a reduced dose of 27mg in superficial bladder cancer. , 2003 .

[66]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[67]  Laurence Collette,et al.  Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. , 2002, European urology.

[68]  J. L. Sebastian,et al.  Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer , 2002, BJU international.

[69]  H. Habermann,et al.  Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? , 2002, Urology.

[70]  O. Bouchot,et al.  [T1 bladder tumors: value of a second endoscopic resection]. , 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[71]  H. Ozen,et al.  Repeated transurethral resection and intravesical BCG for extensive superficial bladder tumors. , 2001, Journal of endourology.

[72]  F. Algaba,et al.  Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. , 2000, The Journal of urology.

[73]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[74]  A. Hartmann,et al.  Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. , 2014, European urology.

[75]  M. Babjuk,et al.  [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.

[76]  G. Mowatt,et al.  Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. , 2010, Health technology assessment.

[77]  J. Gschwend,et al.  An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. , 2010, European urology.

[78]  J. Huguet,et al.  [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy]. , 2010, Actas urologicas espanolas.

[79]  J. Huguet,et al.  Cistectomía radical en tumores vesicales no músculo-infiltrantes que fracasan al tratamiento con bacilo de Calmette-Guérin , 2010 .